-

08:53:01 PM

ALGS Stock News

ALGS - Aligos Therapeutics Inc

11/04/22 8:05 AM

Nasdaq : ALGS

clinical trial

Aligos Therapeutics Presents Clinical Data for its NASH Program and Nonclinical Data for its Chronic Hepatitis B Portfolio at AASLD’s The Liver Meeting® 2022

ALG-055009, a THR-β agonist drug candidate in development as a treatment for NASH, demonstrated dose-dependent reductions in several atherogenic lipids and a favorable pharmacokinetic profile in subjects with hyperlipidemia Aligos’ oral and poster presentations also collectively highlight new data

RHEA-AI

neutral

11/04/22 8:00 AM

Nasdaq : ALGS

clinical trial

Aligos Therapeutics Presents Clinical Data for its Capsid Assembly Modulator, ALG-000184, at AASLD’s The Liver Meeting® 2022

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company

RHEA-AI

neutral

11/02/22 4:05 PM

Nasdaq : ALGS

earnings

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and

RHEA-AI

neutral

10/21/22 9:05 AM

Nasdaq : ALGS

conferencesclinical trial

Aligos Therapeutics to Present Nonclinical and Clinical Data for its Chronic Hepatitis B and NASH Portfolio at AASLD’s The Liver Meeting® 2022

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced seven upcoming poster

RHEA-AI

neutral

10/19/22 4:15 PM

Nasdaq : ALGS

earnings

Aligos Therapeutics to Announce Third Quarter Results November 2, 2022

Aligos Therapeutics, Inc. (Nasdaq: ALGS, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will

RHEA-AI

neutral

10/18/22 7:30 AM

Nasdaq : ALGS

conferencescovid-19

Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA

Aligos Therapeutics, Inc. (Nasdaq: ALGS, the “Company”), a clinical stage biopharmaceutical company focused on developing novel

RHEA-AI

neutral

10/14/22 8:00 AM

Nasdaq : ALGS

Aligos Therapeutics Initiates Dosing In Healthy Volunteers With siRNA Drug Candidate ALG-125755

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage

RHEA-AI

neutral

09/28/22 4:32 PM

Nasdaq : ALGS

Aligos Therapeutics Files Response to Janssen Biopharma Lawsuit and Lodges Counterclaims Alleging Unfair Competition and Promissory Fraud

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, has filed a response to the complaint of, and

RHEA-AI

negative

08/04/22 4:05 PM

Nasdaq : ALGS

earnings

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and

RHEA-AI

neutral

07/27/22 4:05 PM

Nasdaq : ALGS

Aligos Therapeutics to Announce Second Quarter 2022 Results August 4, 2022

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

ALGS Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.aligos.com
Security nameAligos Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2836
Tags
- Health Technology
- Pharmaceuticals: Major

About Aligos Therapeutics Inc

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.